Luo Mengxin, Xu Yongjin, Chen Haifeng, Wu Yiquan, Pang Ao, Hu Junjie, Dong Xiaowu, Che Jinxin, Yang Haiyan
Department of Lymphoma, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, PR China; Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
Department of Lymphoma, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, PR China.
Eur J Med Chem. 2022 Dec 15;244:114847. doi: 10.1016/j.ejmech.2022.114847. Epub 2022 Oct 13.
The Hippo pathway is an evolutionarily conserved signaling pathway that plays critical roles in the tumorigenesis and progression of breast cancer, oral cancer, rectal cancer, colloid cancer, and so on. YAP/TAZ-TEAD complex is a key knot in the Hippo pathway regulating cell proliferation and stem cell functions. Activation or overexpression of this complex has been proved to lead to cell transformation, proliferation and eventually cancerization. In this review, the association between the alterations of hippo pathway and tumorigenesis of various cancer had been elucidated. The structural basis of YAP/TAZ-TEAD complex is analyzed, and the targeting inhibitors are summarized within the medicinal chemistry classification. Moreover, we have also discussed the clinical status and current challenges of these drug candidates, and provide guidance for the future development of inhibitors targeting this pathway, especially YAP/TAZ-TEAD complex.
Hippo信号通路是一条在进化上保守的信号通路,在乳腺癌、口腔癌、直肠癌、结肠癌等肿瘤的发生和发展中起关键作用。YAP/TAZ-TEAD复合体是Hippo信号通路中调节细胞增殖和干细胞功能的关键节点。已证实该复合体的激活或过表达会导致细胞转化、增殖并最终癌变。在这篇综述中,阐明了Hippo信号通路改变与各种癌症肿瘤发生之间的关联。分析了YAP/TAZ-TEAD复合体的结构基础,并在药物化学分类中总结了靶向抑制剂。此外,我们还讨论了这些候选药物的临床现状和当前面临的挑战,并为靶向该通路尤其是YAP/TAZ-TEAD复合体的抑制剂的未来发展提供指导。